---
title: "Stelara (ustekinumab), all indications: Pharmacology questions"
description: "Pharmacology questions on Stelara (ustekinumab) that apply to every indication, each answered with verbatim quotes from the manufacturer's US website for healthcare professionals or documents it links. Topics: Mechanism, Pharmacokinetics, and Components. Questions: How does Stelara work (mechanism of action)? How is Stelara metabolized? Does the Stelara prefilled syringe contain latex? 3 questions quoted from 2 sources."
canonical: "https://www.evicenter.com/medical-information/stelara/pharmacology"
published: "2026-11-14T01:54:55-05:00"
modified: "2026-11-14T15:19:23-05:00"
---

# Stelara (ustekinumab), all indications: Pharmacology questions

Manufacturer: Janssen Biotech, Inc.  
Prescribing information: [Stelara](https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/STELARA-pi.pdf)  
Indication pages: [Plaque psoriasis](https://www.evicenter.com/medical-information/stelara--plaque-psoriasis)

## Mechanism

<a id="stelara-mechanism"></a>

### How does Stelara work (mechanism of action)?

> “STELARA<sup>®</sup> is a human IgG1k  monoclonal antibody that binds with specificity to the p40 protein subunit used by both the interleukin (IL)-12 and IL-23 cytokines<sup>1</sup>
>
> IL-12 and IL-23 are naturally occurring cytokines that are involved in inflammatory and immune responses, such as natural killer cell activation and CD4+ T-cell differentiation and activation<sup>1</sup>
>
> In in vitro models, STELARA<sup>®</sup> was shown to disrupt IL-12– and IL-23–mediated signaling and cytokine cascades by disrupting the interaction of these cytokines with a shared cell-surface receptor chain, IL-12Rβ1<sup>1</sup>
>
> The clinical significance of these characteristics is not fully known”

Source: [STELARA: STELARA® (ustekinumab) Mechanism of Action: Plaque Psoriasis, captured 2026-11-13](https://www.stelarahcp.com/plaque-psoriasis/mechanism-of-action/#:~:text=is%20a%20human%20IgG1k%20monoclonal,characteristics%20is%20not%20fully%20known)

## Pharmacokinetics

<a id="stelara-metabolism"></a>

### How is Stelara metabolized?

> “The metabolic pathway of ustekinumab has not been characterized. As a human IgG1κ 
> monoclonal antibody, ustekinumab is expected to be degraded into small peptides and 
> amino acids via catabolic pathways in the same manner as endogenous IgG.”

Source: [STELARA: Prescribing information, page 7, captured 2026-11-13](https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/STELARA-pi.pdf#page=7)

## Components

<a id="stelara-latex"></a>

### Does the Stelara prefilled syringe contain latex?

> “The needle cover on the prefilled syringe contains dry natural rubber (a 
> derivative of latex). The needle cover should not be handled by persons 
> sensitive to latex.”

Source: [STELARA: Prescribing information, page 3, captured 2026-11-13](https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/STELARA-pi.pdf#page=3)

## Related pages
- [Medical information: Stelara (ustekinumab): All indications](https://www.evicenter.com/medical-information/stelara)
- [Indication](https://www.evicenter.com/medical-information/stelara/indication)
- [Safety](https://www.evicenter.com/medical-information/stelara/safety)
- [Specific populations](https://www.evicenter.com/medical-information/stelara/specific-populations)
- [Drug interactions](https://www.evicenter.com/medical-information/stelara/drug-interactions)
- [Dosing and administration](https://www.evicenter.com/medical-information/stelara/dosing-and-administration)
- [Storage and supply](https://www.evicenter.com/medical-information/stelara/storage-and-supply)
- [Access and coverage](https://www.evicenter.com/medical-information/stelara/access-and-coverage)
